Tumor burden in patients with early and intermediate-stage hepatocellular carcinoma undergoing liver resection: a retrospective multicenter study on clinical and oncological outcomes

被引:3
|
作者
Martin, David [1 ]
Smet, Heloise [1 ]
Costa, Ana Cristina Da Silva [1 ]
Halkic, Nermin [1 ]
Uldry, Emilie [1 ]
Tabrizian, Parissa [2 ]
Schwartz, Myron [2 ]
Mahamid, Ahmad [2 ]
Goumard, Claire [3 ]
Scatton, Olivier [3 ]
Perinel, Julie [4 ]
Adham, Mustapha [4 ]
Demartines, Nicolas [1 ]
Melloul, Emmanuel [1 ,5 ]
机构
[1] Univ Lausanne UNIL, Univ Hosp CHUV, Dept Visceral Surg, Lausanne, Switzerland
[2] Icahn Sch Med Mt Sinai, Recanati Miller Transplantat Inst, Dept Liver Surg, New York, NY USA
[3] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP, Dept Hepatobiliary Surg & Liver Transplantat,CRSA, Paris, France
[4] Hosp Civils Lyon, Edouard Herriot Hosp, Dept Hepatobiliary & Pancreat Surg, Lyon, France
[5] Lausanne Univ Hosp CHUV, Dept Visceral Surg, CH-1011 Lausanne, Switzerland
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; EFFICACY; PROPOSAL; SAFETY; SCORE;
D O I
10.1016/j.hpb.2023.04.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, liver resection (LR) is recommended for early-stage (BCLC-A) hepatocellular carcinoma (HCC) but not for intermediatestage (BCLC-B). This study aimed to assess the outcomes of LR in these patients using a subclassifiMethods: All consecutive patients that underwent LR for BCLC-A and BCLC-B HCC between 01/2010 and 12/2020 in 4 tertiary referral centers were included. Clinical outcomes and overall survival (OS) were assessed in relation to TBS and BCLC stages.Results: Among 612 patients included, 562 were classified as BCLC-A and 50 as BCLC-B. The incidence of overall postoperative complications (56.0 vs 41.5%, p = 0.053) and mortality (0 vs 1.6%, p = 1.000) were similar between BCLC-A and BCLC-B patients. OS was significantly higher for BCLC A/low TBS than BCLC B/low TBS (p = 0.009), while patients with medium and high TBS had similar OS, irrespective of BCLC stage (respectively p = 0.103 and p = 0.343).Conclusions: Patients with medium and high TBS had comparable OS and DFS, irrespective of BCLC A or B stage, and postoperative morbidity was comparable. These results highlight the need for refinement of the BCLC staging system, and LR could be considered for selected intermediate stage (BCLC-B) according to the tumour burden.
引用
收藏
页码:836 / 844
页数:9
相关论文
共 50 条
  • [31] High Visceral Adipose Tissue Density Correlates With Unfavorable Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Li, Qiang
    Zhang, Lei
    Hou, Zhong-Heng
    Zhao, Dong-Xu
    Li, Jian-Bin
    Zhang, Shuai
    Yin, Yu
    Ni, Cai-Fang
    Chen, Tao
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [32] Tumor burden score as a prognostic factor in patients with intermediate and locally advanced hepatocellular carcinoma undergoing liver resection: an attempt to extend resectability criteria
    Nandy, Kunal
    Patkar, Shraddha
    Varty, Gurudutt
    Shah, Tanvi
    Pawar, Akash
    Goel, Mahesh
    HPB, 2024, 26 (09) : 1180 - 1189
  • [33] Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study
    Lu, Linbin
    Shen, Lujun
    Wu, Zhixian
    Shi, Yanhong
    Hou, Peifeng
    Xue, Zengfu
    Lin, Cheng
    Chen, Xiong
    ECLINICALMEDICINE, 2022, 47
  • [34] A prospective observational study of lenvatinib as an initial treatment for patients with intermediate-stage hepatocellular carcinoma
    Kobayashi, Satoshi
    Numata, Kazushi
    Fukushima, Taito
    Ueno, Makoto
    Moriya, Satoshi
    Chuma, Makoto
    Tsuruya, Kota
    Hirose, Shunji
    Kagawa, Tatehiro
    Hattori, Nobuhiro
    Matsunaga, Kotaro
    Watanabe, Tsunemasa
    Uojima, Haruki
    Hidaka, Hisashi
    Kusano, Chika
    Morimoto, Manabu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [35] Variable survival outcomes in Australian patients with very early-stage and early-stage hepatocellular carcinoma: A retrospective multicenter cohort study
    Abdelmalak, J.
    Lam, E.
    Greenhill, E.
    Zalcberg, J.
    Roberts, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 71 - 72
  • [36] Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study
    Zheng, Yitao
    Xiang, Yanjun
    Shi, Hongqi
    Lin, Zhuoqun
    Cheng, Shuqun
    Zhu, Jiuting
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1079 - 1093
  • [37] Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria
    Tsilimigras, Diamantis, I
    Mehta, Rittal
    Paredes, Anghela Z.
    Moris, Dimitrios
    Sahara, Kota
    Bagante, Fabio
    Ratti, Francesca
    Marques, Hugo P.
    Silva, Silvia
    Soubrane, Olivier
    Lam, Vincent
    Poultsides, George A.
    Popescu, Irinel
    Grigorie, Razvan
    Alexandrescu, Sorin
    Martel, Guillaume
    Workneh, Aklile
    Guglielmi, Alfredo
    Hugh, Tom
    Aldrighetti, Luca
    Endo, Itaru
    Spolverato, Gaya
    Umberto, Cillo
    Pawlik, Timothy M.
    ANNALS OF SURGERY, 2020, 272 (04) : 574 - 581
  • [38] Comparison of prognosis after hepatic resection of hepatocellular carcinoma between intermediate stage tumor and early stage tumor
    Arita, J.
    Kokudo, T.
    Akamatsu, N.
    Kaneko, J.
    Ishizawa, T.
    Hasegawa, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Transcatheter Arterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Clinical Outcome and Safety in Elderly Patients
    Nishikawa, Hiroki
    Kita, Ryuichi
    Kimura, Toru
    Ohara, Yoshiaki
    Takeda, Haruhiko
    Sakamoto, Azusa
    Saito, Sumio
    Nishijima, Norihiro
    Nasu, Akihiro
    Komekado, Hideyuki
    Osaki, Yukio
    JOURNAL OF CANCER, 2014, 5 (07): : 590 - 597
  • [40] Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients
    Caihua Zhu
    Bing Dai
    Hua Zhan
    Ruoyu Deng
    Irish Journal of Medical Science (1971 -), 2023, 192 (3): : 1065 - 1071